Cytosorbents Corporation (CTSO)
NASDAQ: CTSO · Real-Time Price · USD
1.090
-0.070 (-6.03%)
Apr 25, 2025, 12:08 PM EDT - Market open
Cytosorbents Revenue
In the year 2024, Cytosorbents had annual revenue of $35.59M with 14.51% growth. Cytosorbents had revenue of $6.52M in the quarter ending December 31, 2024, with 91.65% growth.
Revenue (ttm)
$35.59M
Revenue Growth
+14.51%
P/S Ratio
1.77
Revenue / Employee
$238,889
Employees
149
Market Cap
68.13M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 35.59M | 4.51M | 14.51% |
| Dec 31, 2023 | 31.08M | -3.60M | -10.39% |
| Dec 31, 2022 | 34.69M | -8.48M | -19.64% |
| Dec 31, 2021 | 43.17M | 2.16M | 5.27% |
| Dec 31, 2020 | 41.00M | 16.06M | 64.35% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 410.06B |
| Johnson & Johnson | 89.33B |
| Merck & Co. | 64.17B |
| AbbVie | 56.33B |
| AstraZeneca | 54.07B |
| Novartis AG | 51.72B |
| Eli Lilly and Company | 45.04B |
| Thermo Fisher Scientific | 42.90B |
CTSO News
- 4 days ago - CytoSorbents Receives Approximately $1.7 Million from the New Jersey Business Tax Certificate Transfer Program - PRNewsWire
- 8 days ago - CytoSorbents Appoints Melanie Grossman, CPA as Vice President and Corporate Controller - PRNewsWire
- 11 days ago - CytoSorbents Appoints Thomas Shannon as Vice President of Marketing for North America - PRNewsWire
- 21 days ago - CytoSorbents Extends Expiration Date of Outstanding Series B Right Warrants - PRNewsWire
- 24 days ago - Cytosorbents Corporation (CTSO) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 24 days ago - CytoSorbents Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights - PRNewsWire
- 5 weeks ago - CytoSorbents Reschedules Earnings Release to March 31, 2025 to Allow Additional Time to Complete Annual Audit - PRNewsWire
- 7 weeks ago - CytoSorbents Postpones Earnings Release to Allow More Time to Complete Annual Audit Following the Passing of Corporate Controller - GlobeNewsWire